[12] Patent
[11] Patent No.:GC0010749  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2019                63/2019  
Number of the Decision to Grant the Patent:2019/156875
Date of the Decision to Grant the Patent:11/Sep/2019

[21] Application No.:GC 2014-27056

[22] Filing Date:27/4/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
EP
29/4/2013
15/1/2014
13165741.3
14151318.4

[72] Inventors:1- Guido Hartmann ،2- Joerg Thomas Regula،3- Matthias Rueth ،4- Wolfgang Schaefer،5- Tilman Schlothauer

[73] Owner: F. Hoffmann - La Roche AG, 124 Grenzacherstrasse , Basle, CH-4070, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: C07K 16/22, 16/28 (2006.01)

[56] Cited Documents:

-WO 2008/077546 A1 (HOFFMANN LA ROCHE [CH] ; KOLL HANS [DE] ; KUENKELE KLAUS-PETER [DE] ; MOS) 3 July 2008
-WO 2009/126304 A1 (BIOGEN !DEC INC [US] ; HARI HARAN KANDASAMY [US] ; DONG JIANYING [US]) 15 October 2009
 
Examiner: PH. Neda J. AlMuallem

[54] FCRN-BINDING ABOLISHED ANTI-IGF-1R ANTIBODIES AND THEIR USE IN THE TREATMENT OF VASCULAR EYE DISEASES
[57] Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
No. of claims: 32     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.